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Summary
Purpose: Sphingolipids are important signaling mol-
ecules mediating cell survival, proliferation, cell cycle regu-
lation and apoptosis. Ceramide is the most vital sphingolipid 
which induces growth arrest, senescence, and apoptosis. In this 
study, we aimed to determine the roles of sphingosine kinase-1 
(SK-1) and glucosylceramide synthase (GCS) genes in pacli-
taxel, doxorubicin, tamoxifen, cyclophosphamide and docetax-
el induced apoptosis in human MCF-7 breast cancer cells.
Methods: IC50 values (drug concentration inhibit-
ing cell growth by 50%) of the anticancer agents were cal-
culated using XTT cell proliferation assay. Changes in mi-
tochondrial membrane potential (MMP) were determined 
using JC-1 assay kit. Changes in the mRNA levels of SK-1 
and GCS genes were measured by using RT-PCR technique.
Results: The results demonstrated significant decrease 
in cellular proliferation and increase in loss of MMP in a 
dose-dependent manner. Paclitaxel, doxorubicin, tamoxifen, 
cyclophosphamide and docetaxel application downregulated 
SK-1 expression while paclitaxel, tamoxifen, cyclophospha-
mide and docetaxel but not doxorubicin downregulated GCS 
comparing to untreated control cells.
Conclusion: These results show for the first time that 
these agents induce apoptosis in MCF-7 cells by downregu-
lating the antiapoptotic SK-1 and GCS genes that may result 
in accumulation of apoptotic ceramides.
Key words: bioactive sphingolipids, breast cancer, glucosyl-
ceramide synthase, MCF-7, sphingosine kinase-1
Introduction
Sphingolipids are important structural lipids me-
diating the fluidity and sub-domain structure of the lip-
id bilayers [1]. All membrane sphingolipids are com-
posed of a long-chain sphingoid backbone and a fatty 
acid with an amide bond linkage [2]. There are differ-
ent bioactive sphingolipids such as ceramide, glucosyl-
ceramide, sphingosine, and sphingosine-1-phosphate 
(S1P). In addition to structural control of sphingolipids, 
these bioactive sphingolipids act as bioeffector mol-
ecules and control cellular processes such as cell sur-
vival, cell proliferation, cell growth and cell death [3].
Under stress conditions such as UV irradiation 
or chemotherapeutic agents, cell signaling through the 
sphingolipids starts via de novo pathway by ceramide 
synthase or salvage pathway by sphingomyelinases. 
Both pathways provide intracellular accumulation of 
ceramides. Ceramide is the central molecule within 
sphingolipids mediating antiproliferative responses 
such as senescence, growth arrest, and apoptosis. Many 
apoptosis-inducing factors promote ceramide genera-
tion before triggering apoptotic cascades [3-6]. Also, 
inhibition of ceramide metabolism enzymes increases 
the intracellular ceramide level resulting in apoptosis. 
Once ceramide is generated, ceramidases convert ce-
ramide to sphingosine which is also an anti-prolifera-
tive bioactive sphingolipid. Phosphorylation of apop-
totic sphingosine by SK-1 generates an antiapoptotic 
metabolite, S1P. Unlike ceramide and sphingosine, 
sphingosine-1-phosphate is a pro-survival molecule 
inducing cell proliferation, cell growth and inhibit-
ing apoptosis [6-8]. Glucosylceramide is another pro-
survival molecule, similar to S1P, converted from ce-
ramide by GCS. Transfer of glucose to ceramide gener-
ates glucosylceramide and glucosylceramide is known 
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Measurement of cell growth by XTT
The IC50 values of paclitaxel, doxorubicin, tamox-
ifen, cyclophosphamide and docetaxel were determined 
by XTT cell proliferation assay as previously described 
[18,19]. Briefly, 1×104 cells were seeded into 96-well 
plates containing 200 µl growth medium and were incu-
bated at 37° C in 5% CO2 for 24 h. Then, they were ex-
posed to increasing concentrations of the agents separate-
ly and incubated at 37° C in 5% CO2 for 72 h. After that, 
the cells were treated with the 40 µl XTT for 4 h and then 
the plates were read under 490 nm wavelength by Elisa 
Reader (Thermo Electron Corporation Multiskan Spec-
trum, Finland). Cell proliferation plots obtained from 
the measurement were used to calculate the IC50 values.
Measurement of mitochondrial membrane potential 
(MMP)
MMP in MCF-7 cells was determined by using 
APO LOGIX JC-1 Assay Kit (Cell Technology, CA) 
as previously described [20]. Briefly, the cells that had 
been induced to apoptosis with exposure to paclitax-
el, doxorubicin, tamoxifen, cyclophosphamide and 
docetaxel for 72 h were centrifuged at 1000 rpm for 10 
min. The collected pellets were treated with 500 µl JC-
1 dye and incubated at 37° C in 5% CO2 for 15 min. Af-
ter incubation, they were centrifuged at 1000 rpm for 5 
min. Supernatants were removed and the pellets were 
resuspended with 2 ml of assay buffer. Then, they were 
centrifuged at 1000 rpm for 5 min. Pellets were resus-
pended again by adding 500 µl of assay buffer. Then, 
150 µl from each sample were added into 96-well plate, 
and the plates were read under 585/590 nm and 510/ 
527 nm wavelengths for the aggregate red form and the 
green monomeric form, respectively, by fluorescence 
Elisa reader (Thermo Varioskan Spectrum, Finland).
Total RNA isolation and reverse transcriptase-poly-
merase chain reaction (RT-PCR)
mRNA levels of SK-1 and GCS genes were de-
termined in docetaxel, doxorubicin, paclitaxel, cyclo-
phosphamide, and tamoxifen applied to MCF-7 cells 
by RT-PCR. To this aim, total RNA was isolated from 
the cells that had been induced to apoptosis through 
treatment with paclitaxel, doxorubicin, tamoxifen, cy-
clophosphamide and docetaxel for 72 h by using Nu-
cleospin RNA isolation kit (Macherey-Nagel) accord-
ing to the manufacturer instructions. Then, 1 µg of RNA 
was reverse-transcribed by using reverse transcriptase 
(Fermentas, USA). First, the reaction tubes were incu-
bated at room temperature for 10 min. Then, they were 
to be associated with drug resistance in different types 
of cancers [9].
Breast cancer is the most common cancer type 
among women. Breast cancer can be treated surgically, 
with systemic therapies (chemotherapy and endocrine 
therapy) and radiotherapy. However, limitations in che-
motherapy are a formidable obstacle in breast cancer 
treatment [10]. Cancer cells have inherited or acquired 
resistance in order to reduce the intracellular levels of 
chemotherapeutic agents. This multidrug resistance 
(MDR) phenomenon is very common and known to be 
linked to several mechanisms such as overexpression of 
MDR genes and bcl-2 [11]. Recent studies showed that 
the antiapoptotic sphingolipid glucosylceramide and 
S1P have important effects on chemotherapeutic resis-
tance in ovarian and breast cancer [12-14].
A good number of widely used anticancer agents 
for the treatment of breast cancer is available. The mi-
crotubule stabilizing agents paclitaxel and docetaxel 
have been used since 1990s for breast cancer treatment, 
being members of the taxane family. They function at 
the microtubule dynamics resulting in cell cycle arrest 
and induction of apoptosis [15]. Tamoxifen is a wide-
ly used anticancer agent used in hormone-responsive 
breast cancer types. Inhibition of estrogen receptor by 
tamoxifen induces cell cycle arrest resulting in apopto-
sis [16]. Doxorubicin is one of the most effective anthra-
cyclines that intercalates DNA bases, DNA unwinding, 
reactive oxygen generation, and changes in membrane 
structure. Thus, doxorubicin results in several important 
processes of a cell, such as cellular growth and differen-
tiation, and programmed cell death [17]. Cyclophospha-
mide is also an important alkylating agent for the treat-
ment of breast cancer [15].
In this study, we examined the involvement of SK-
1 and GCS genes in paclitaxel, doxorubicin, tamoxifen, 
cyclophosphamide and docetaxel induced apoptosis in 
human MCF-7 breast cancer cells.
Methods
Cell lines and culture conditions
Human MCF-7 breast cancer cells were kindly 
provided by Dr. Ali Ugur Ural from Gulhane Military 
Medical Academy. Anticancer agents used in this study 
(paclitaxel, doxorubicin, tamoxifen, cyclophosphamide 
and docetaxel) were kindly provided by Dr. Guray Say-
dam from Ege University Hematology Department. 
These cells were maintained in RPMI-1640 growth me-
dium containing 10% fetal bovine serum and 1% pen-
icillin-streptomycin (Invitrogen) at 37° C in 5% CO2.
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incubated at 42° C for 50 min. After incubation at 95° 
C for 5 min and on ice for 5 min, the cDNAs were used 
for the mRNA level detection of β-actin, SK-1 and GCS 
genes by PCR reaction. The primer sequences and the 
PCR conditions were as follows:
β-actin forward 5’CAGAGCAAGAGAGGCATCCT3’,
β-actin reverse 5’TTGAAGGTCTCAAACATGAT3’,
SK-1 forward 5’CCGACGAGGACTTTGTGCTAAT3’,
SK-1 reverse 5’GCCTGTCCCCCCAAAGCATAAC3’,
GCS forward 5’ATGACAGAAAAAGTAGGCT3’,
GCS reverse 5’GGACACCCCTGAGTGGAA3’.
2 µl cDNA were used for the amplification of β-
actin, SK-1, and GCS [20]. PCR reactions were per-
formed for 35 cycles at 94° C for 5 min, 94° C for 1 min, 
53° C for 1 min, 72° C for 1 min and 72° C for 5 min. 
Finally, RT-PCR products were run on 2% agarose gel 
for 1 h at 90 V.
Statistical analysis
Statistical significance was determined using two-
way analysis of variance, and p<0.05 was considered 
significant.
Results
All agents showed a dose-dependent cytotoxicity 
on human MCF-7 breast cancer cells.
The results revealed that increased concentrations 
of docetaxel (Figure 1A), doxorubicin (Figure 1B), pa-
clitaxel (Figure 1C), cyclophosphamide (Figure 1D), 
and tamoxifen (Figure 1E) expressed antiproliferative 
effects on human MCF-7 breast cancer cells as shown 
by XTT cell proliferation assay. There was dose-de-
pendent decrease in the proliferation of MCF-7 cells in 
response to paclitaxel, doxorubicin, tamoxifen, cyclo-
phosphamide and docetaxel as compared with the un-
treated controls. IC50 values of paclitaxel, doxorubicin, 
tamoxifen, cyclophosphamide and docetaxel were cal-
culated as 137 nM, 47 µM, 47 µM, 20 mM and 10 nM, 
respectively (Figure 1).
The MMP increased significantly with the expo-
sure of increased concentrations of the agents in MCF-7 
cells comparing to untreated control cells (Figure 2).
Significant decrease in mRNA levels of SK-1 was 
registered in MCF-7 cells exposed to increasing con-
centrations of docetaxel, doxorubicin, paclitaxel, cyclo-
phosphamide, and tamoxifen in a dose-dependent man-
ner as compared to untreated cells and normalized to β-
actin levels (Figure 3). Similar decrease was obtained in 
GCS levels in response to docetaxel, paclitaxel, cyclo-
phosphamide, and tamoxifen in a dose-dependent man-
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Figure 1. Antiproliferative effects of docetaxel (A), doxorubicin 
(B), paclitaxel (C), cyclophosphamide (D), and tamoxifen (E) on 
MCF-7 cells. XTT assay was performed using triplicate samples in 
at least 2 independent experiments. The error bars represent the stan-
dard deviations. Statistical significance was determined using two-
way analysis of variance, and p<0.05 was considered significant.
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sociated with the development of MDR in many cancer 
types [1]. On the other hand, ceramide can also be con-
verted to antiapoptotic and prosurvival molecule, S1P, 
by SK-1. That’s why both glucosylceramide and S1P 
levels have been used as resistance markers in various 
types of cancers. However, stress conditions including 
chemotherapy can induce apoptosis through downregu-
lation of GCS and SK-1 genes.
In this study, we have shown that docetaxel, doxo-
rubicin, paclitaxel, cyclophosphamide, and tamoxifen 
have significant cytotoxic effects on human MCF-7 
breast cancer cells in a dose-dependent manner. In or-
der to confirm the XTT cell proliferation data, we deter-
mined the loss of MMP in response to these agents. The 
results revealed that they all induce apoptosis through 
MMP in a dose-dependent manner. Although the mech-
anisms of action of all the drugs are well known, the 
roles of SK-1 and GCS in docetaxel-, doxorubicin-, pa-
clitaxel-, cyclophosphamide-, and tamoxifen-induced 
apoptosis have not been examined before.
Our and different other groups have shown that 
there is significant increase in the expression levels of 
GCS and intracellular concentrations of glucosylce-
ramide in drug-resistant cancer cells. Liu et al. have 
shown that GCS introduced in MCF-7 cells resulted in 
resistance to doxorubicin and ceramide comparing to 
wild type cells [21]. Cabot et al. have also shown that 
introduction of GCS sense and antisense cDNAs into 
doxorubicin-resistant human breast carcinoma cells af-
fected the results of sensitivity and resistance of breast 
cancer cells [22]. On the other hand, it was shown that 
inhibition of GCS expression by the oligodeoxyribonu-
cleotides resulted in increase of sensitivity of doxorubi-
cin-resistant MCF-7 cells to doxorubicin [23]. There are 
a number of studies supporting the idea that overexpres-
sion of GCS also results in increased expression levels 
of a strong transporter gene, MDR1, in various types of 
cancers [24-26]. In this study, we examined the expres-
ner while no changes in expression levels of GCS were 
detected in response to doxorubicin (Figure 3).
Discussion
Sphingolipids are known as important structural 
lipids. However, several studies showed that the roles 
of sphingolipids in most cellular processes are vital and 
related with cancer pathogenesis and treatment [1]. Ce-
ramide is the most important biologically active sphin-
golipid acting as an antiproliferative molecule. Stress 
conditions increase the intracellular levels of ceramide 
through de novo synthesis or sphingomyelin hydroly-
sis. Conversion of ceramide to antiapoptotic glucosyl-
ceramide by GCS results in the decrease of intracellular 
ceramide levels and this conversion is known to be as-
Figure 2. Percent changes in cytoplasmic/mitochondrial JC-1 in MCF-7 cells exposed to docetaxel (A), doxorubicin (A), paclitaxel (A), 
cyclophosphamide (A), and tamoxifen (B).
Figure 3. mRNA levels of GCS, SK-1 and beta actin in docetaxel, 
doxorubicin, paclitaxel, cyclophosphamide, and tamoxifen exposed 
MCF-7 cells. Expression levels of GCS, SK-1 and beta actin genes 
were determined by RT-PCR. Expression levels of beta actin was 
detected as an internal positive control.
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11. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends 
Cell Biol 2001; 11: 22-26.
12. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot 
MC. Glucosylceramide: a marker for multiple-drug resistant 
cancers. Anticancer Res 1998; 18: 475-480.
13. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accu-
mulation of glucosylceramides in multidrug-resistant cancer 
cells. J Biol Chem 1996; 271: 19530-19536.
14. Johnson KR, Johnson KY, Becker KP, Bielawski J, Mao C, 
Obeid LM. Role of human sphingosine-1-phosphate phos-
phatase 1 in the regulation of intra- and extracellular sphingo-
sine-1-phosphate levels and cell viability. J Biol Chem 2003; 
278: 34541-34547.
15. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, 
microtubules and chemoresistant breast cancer. Biochim Bio-
phys Acta 2008; 1785: 96-132.
16. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced 
apoptosis. Apoptosis 2001; 6: 469-477.
17. Baran Y, Gür B, Kaya P, Ural AU, Avcu F, Gunduz U. Upregu-
lation of multi drug resistance genes in doxorubicin resistant 
human acute myelogenous leukemia cells and reversal of the 
resistance. Hematology 2007; 12: 511-517.
18. Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resis-
tance to imatinib in human chronic myeloid leukemia cells. 
Hematology 2007; 12: 497-503.
19. Piskin Ö, Özcan MA, Özsan GH et al. Synergistic effect of 
imatinib mesylate and fludarabine combination on Philadel-
phia chromosome-positive chronic myeloid leukemia cell 
lines. Turk J Hemat 2007; 24: 23-27.
20. Baran Y, Salas A, Senkal CE et al. Alterations of ceramide/
sphingosine 1-phosphate rheostat involved in the regula-
tion of resistance to imatinib-induced apoptosis in K562 hu-
man chronic myeloid leukemia cells. J Biol Chem 2007; 282: 
10922-10934.
21. Liu YY, Han TY, Giuliano AE, Cabot MC. Expression of glu-
sion levels of GCS in response to a number of anticancer 
agents to determine whether GCS is involved in apop-
tosis triggered by these agents. Interestingly, our results 
showed that there was significant decrease in the expres-
sion levels of GCS in MCF-7 cells exposed to docetaxel, 
paclitaxel, cyclophosphamide, and tamoxifen but not to 
doxorubicin in a dose-dependent manner.
Increase in intracellular concentrations of the pro-
survival metabolite S1P has been used as a marker for 
drug resistance. There are a number of studies showing 
increased expression levels of SK-1 and intracellular 
concentrations of S1P in cancer cells and in drug resistant 
cancer cells [1,3]. On the other hand, we and others have 
shown that under stress conditions generated by apply-
ing of DNA damaging agents like actinomycin D, etopo-
side and γ-irradiation, the expression levels of SK-1 are 
downregulated in different types of cancers [19,27,28]. 
In parallel with these results, inhibition of SK-1 gene ex-
pression by siRNA application or application of SK-1 in-
hibitors results in increased sensitivity of cancer cells to 
chemotherapeutics [19,29]. In our study, we have shown 
that all anticancer agents tested (docetaxel, doxorubicin, 
paclitaxel, cyclophosphamide, and tamoxifen) resulted 
in significant repression of expression levels of SK-1 
gene in a dose-dependent manner in MCF-7 cells.
In conclusion, we aimed to assess the roles of an-
tiapoptotic and prosurvival genes SK-1 and GCS in 
docetaxel, doxorubicin, paclitaxel, cyclophosphamide, 
and tamoxifen induced apoptosis in MCF-7 human 
breast cancer cells. We have shown for the first time that 
the anticancer agents docetaxel, paclitaxel, doxorubicin, 
cyclophosphamide and tamoxifen, induce apoptosis by 
downregulating the expression levels of the antiapoptot-
ic GCS and SK-1 genes and thus increasing the intracel-
lular concentrations of the apoptotic ceramide, besides 
their known effects. The results of this study may sup-
port the idea that SK-1 and GCS can be novel targets for 
cancer treatment.
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